Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens.

Antimicrobial agents and chemotherapy - 1 Jun 2012

Garrido Carolina, Villacian Jorge, Zahonero Natalia, Pattery Theresa, Garcia Federico, Gutierrez Felix, Caballero Estrella, Van Houtte Margriet, Soriano Vincent, de Mendoza Carmen

Abstract excerpt

The failure of raltegravir (RAL) is generally associated with the selection of mutations at integrase position Y143, Q148, or N155. However, a relatively high proportion of failures occurs in the absence of these changes. Here, we report the phenotypic susceptibilities to RAL and elvitegravir (EVG) for a large group of HIV-infected patients failing on RAL-containing regimens. Plasma from HIV-infected individuals...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Viral
Share to Genotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Infections

Share to HIV Integrase Inhibitors

Share to Molecular Sequence Data

Share to Pyrrolidinones

Share to Quinolones

Share to Raltegravir Potassium

Source

Open in PubMed Open full text

Identifiers

PMID: 22450969
DOI: 10.1128/AAC.06170-11
PMCID: PMC3370736

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens.PMID 22450969Read ↗

Emerging patterns and implications of HIV-1 integrase inhibitor resistanceSemantic proximity Read ↗

Cross-Resistance Profile Determination of Two Second-Generation HIV-1 Integrase Inhibitors Using a Panel of Recombinant Viruses Derived from Raltegravir-Treated Clinical IsolatesSemantic proximity Read ↗

Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response.Semantic proximity Read ↗

Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy.Semantic proximity Read ↗

High frequency of dolutegravir resistance in patients failing a raltegravir-containing salvage regimen.Semantic proximity Read ↗

HIV drug resistance against strand transfer integrase inhibitors.Semantic proximity Read ↗

In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravirSemantic proximity Read ↗

Development of elvitegravir resistance and linkage of integrase inhibitor mutations with protease and reverse transcriptase resistance mutations.Semantic proximity Read ↗

Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure in the ARCA database.Semantic proximity Read ↗

Accumulation of Multiple Mutations In Vivo Confers Cross-Resistance to New and Existing Integrase InhibitorsSemantic proximity Read ↗

Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir.Semantic proximity Read ↗

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.